Articles tagged with Fibrosis
A new laboratory test has been developed to identify patients at high risk of developing cirrhosis after a liver transplant due to hepatitis C. The test targets hepatic stellate cells, which can produce collagen leading to scarring in infected patients.
Researchers identified alpha-smooth muscle actin (alpha-SMA) as a reliable marker for predicting fibrosis development after liver transplant. Studies showed that HSC activation was associated with advanced fibrosis, suggesting a potential biomarker for early intervention and treatment.
Researchers found a common genetic defect that prevents proper lung repair, increasing risk of idiopathic pulmonary fibrosis in families with a history of the disease. Smoking is also a major contributor to the disease, particularly among those with a family history.
A study identified osteopontin as a protein more prevalent in lungs of patients with idiopathic pulmonary fibrosis. The protein increased cell proliferation and movement involved in lung fibrosis, offering potential new treatment targets.
Researchers found that nicotine caused a significant increase in atrial interstitial fibrosis and electrical remodeling in hearts with myocardial infarction, leading to atrial flutter. The study suggests a causal link between nicotine and atrial flutter, potentially informing new therapeutic strategies.
Researchers found that transplanted bone marrow cells reduced liver fibrosis in mice treated with carbon tetrachloride. The treatment also improved survival rates and increased serum albumin levels, suggesting a new concept for treating liver fibrosis.
A novel AT2R gene transfer approach has been shown to prevent hypertension-related enlarged heart, cardiac fibrosis. The study found that the procedure prevented the heart from enlarging and prevented thickening of the ventricular walls.
Researchers found elevated caspase levels in HCV patients with normal aminotransferase levels, associated with higher stages of liver fibrosis. The study suggests that measuring caspase-mediated CK-18 cleavage in serum may be a more sensitive method to detect liver fibrosis in chronic HCV infection.
Pulmonary fibrosis occurs when normal lung tissue is replaced with thick scar tissue, impairing oxygen flow. Researchers have discovered that TGF-beta causes apoptosis in epithelial cells before fibrosis develops, paving the way for potential treatments by blocking cell death.
Researchers found that a specific adult stem cell travels to the lung through the bloodstream and produces collagen, leading to scar tissue formation. Blocking this mechanism may reduce pulmonary fibrosis, offering new treatments for related disorders like rheumatoid arthritis.
Researchers have discovered that bone marrow-derived stem cells are present in the lungs of mice with pulmonary fibrosis. This finding suggests a new approach to treating the disease using stem cell therapy. Understanding how these stem cells engraft and interact with the lung tissue could lead to improved treatment outcomes.
Researchers at Yale University demonstrate that OspC is critical for Borrelia burgdorferi's ability to invade tick salivary glands and be transmitted to humans. Meanwhile, studies on hereditary spastic paraplegia and idiopathic pulmonary fibrosis reveal potential new targets for treatment.
Researchers developed a new composite score combining CT imaging and pulmonary function testing to assess treatment effects in young cystic fibrosis patients. A new test was also developed to predict increased mortality risk in idiopathic interstitial pneumonia patients with significant decline in pulmonary function.
A new Composite Physiologic Index (CPI) effectively tracks pulmonary fibrosis in patients and provides a more accurate prognostic indicator for interstitial pneumonia. Additionally, researchers explore the potential of stem cells to treat acute lung injury and its severe form, ARDS.
A randomized controlled trial found that sildenafil reduced pulmonary blood resistance, a key indicator of pulmonary hypertension. The study suggests sildenafil could be a promising candidate for long-term treatment of secondary pulmonary hypertension in lung fibrosis. Controlled trials are needed to confirm the findings.